D. González de Requena

发表

Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.

V. Soriano, J. González-lahoz, F. Blanco, 2003, AIDS patient care and STDs.

Ultrasensitive assessment of residual HIV viraemia in HAART‐treated patients with persistently undetectable plasma HIV‐RNA: A cross‐sectional evaluation

G. d’Ettorre, V. Vullo, E. Nicastri, 2009, Journal of medical virology.

Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.

A. Lazzarin, G. di Perri, A. Calcagno, 2013, Journal of Antimicrobial Chemotherapy.

Liver toxicity caused by nevirapine.

V. Soriano, I. Jiménez-Nácher, M. Núñez, 2002, AIDS.

Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study

G. di Perri, A. Calcagno, I. Dal Conte, 2012, Infection.

A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.

G. di Perri, A. D’Avolio, M. Siccardi, 2008, Journal of chromatographic science.

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz.

V. Soriano, J. González-lahoz, A. Rodríguez-Albariño, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug–drug interactions and tolerance in combining antituberculosis and antiretroviral therapy

F. Gobbi, G. di Perri, S. Audagnotto, 2005, Expert opinion on drug safety.

Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function

G. di Perri, A. Calcagno, I. Motta, 2013, Antimicrobial Agents and Chemotherapy.

Clinical benefit of interventions driven by therapeutic drug monitoring

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2005, HIV medicine.

[Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].

G. di Perri, A. Calcagno, S. Bonora, 2006, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2000, AIDS.

Higher efavirenz plasma levels correlate with development of insomnia.

V. Soriano, J. González-lahoz, I. Jiménez-Nácher, 2001, Journal of acquired immune deficiency syndromes.

Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment

M. Rizzetto, G. di Perri, A. Calcagno, 2012, Therapeutic drug monitoring.

Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.

V. Soriano, C. de Mendoza, J. González-lahoz, 2004, AIDS patient care and STDs.

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.

V. Soriano, I. Jiménez-Nácher, O. Gallego, 2004, AIDS research and human retroviruses.

Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.

P. Vitiello, Ottavia Viganò, G. di Perri, 2011, The Journal of antimicrobial chemotherapy.

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.

G. di Perri, A. D’Avolio, M. Siccardi, 2008, The Journal of antimicrobial chemotherapy.

Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Primary Resistance Mutations in a Clinical Setting

F. D. De Rosa, G. di Perri, M. Boffito, 2005, Antimicrobial Agents and Chemotherapy.

Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.

V. Soriano, C. de Mendoza, A. Corral, 2003, AIDS Research and Human Retroviruses.

Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations.

V. Soriano, C. de Mendoza, I. Jiménez-Nácher, 2003, AIDS.

Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations

V. Soriano, A. Corral, I. Jiménez-Nácher, 2004, AIDS.

Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.

A. Lazzarin, G. di Perri, A. Calcagno, 2011, The Journal of antimicrobial chemotherapy.